Boehringer Ingelheim and Connexios Life Sciences Enter Agreement for AMPK Activators
Boehringer Ingelheim and Connexios Life Sciences announce global research collaboration agreement for AMPK agonists.
Boehringer Ingelheim and Connexios Life Sciences, a Bangalore based biotechnology company, reported an exclusive global research collaboration agreement for AMPK agonists for the treatment of patients with Type 2 Diabetes.
As part of the agreement, Boehringer Ingelheim obtains global rights to CNX-012, Connexios Life Sciences’ program on AMPK activators. The program includes CNX-570 and other compounds in early pre-clinical development. Boehringer Ingelheim will be responsible for all further development and commercialization of the candidates from the AMPK program. Further terms and financial details were not disclosed.
Source: Boehringer Ingelheim
